Biography
Dr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an assistant professor in the Department of Medicine in the Division of Blood & Marrow Transplantation and Cellular Therapy.
She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, following her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. The research in her lab focuses on investigations of the biology of chimeric antigen receptor (CAR) T cells to improve the efficacy and safety of this therapy (1) by investigating donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by assessing mechanisms for the impact of the intestinal microbiome on CAR T cell response (Nature Medicine, 2022).
Dr. Smith presents the findings of her research at regional, national, and international conferences. Further, she has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, among others Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves a peer reviewer for publications in journals, such as NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She also has contributed to chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
She has earned numerous honors; the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar.
Dr. Smith is a member of the ASH Committee on Emerging Gene and Cell Therapies and the ASH Committee on Diversity, Equity & Inclusion. Additionally, she serves on committees within the institution and professional organizations focused on promoting diversity among hematology and cell therapy specialists.
She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, following her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. The research in her lab focuses on investigations of the biology of chimeric antigen receptor (CAR) T cells to improve the efficacy and safety of this therapy (1) by investigating donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by assessing mechanisms for the impact of the intestinal microbiome on CAR T cell response (Nature Medicine, 2022).
Dr. Smith presents the findings of her research at regional, national, and international conferences. Further, she has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, among others Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves a peer reviewer for publications in journals, such as NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She also has contributed to chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
She has earned numerous honors; the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar.
Dr. Smith is a member of the ASH Committee on Emerging Gene and Cell Therapies and the ASH Committee on Diversity, Equity & Inclusion. Additionally, she serves on committees within the institution and professional organizations focused on promoting diversity among hematology and cell therapy specialists.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification, American Board of Internal Medicine, Medical Oncology
- Board Certification, American Board of Internal Medicine, Hematology
- Board Certification, American Board of Internal Medicine, Internal Medicine
-
- Fellowship, Memorial Sloan Kettering Cancer Center, Medical Oncology and Hematology
- Residency, University of Texas Southwestern Medical School, Internal Medicine
- Internship, University of Texas Southwestern Medical School, Internal Medicine
- Medical Education, University of Texas Southwestern Medical School
Honors & Awards
- Abstract Achievement Award, American Society of Hematology
- ASH Minority Medical Student Award, American Society of Hematology (ASH)
- Best Basic Science Abstract, European Society for Blood and Marrow Transplantation
-
- Clinical Research Training Course, American Society for Transplantation and Cellular Therapy
- Translational Research Training in Hematology, American Society of Hematology & European Hematology Association
- Women in Cancer Immunotherapy Network Leadership Institute, Society for Immunotherapy of Cancer
Administrative Appointments
- Assistant Professor, Division of Blood & Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine (2021 - Present)
-
Publications
-
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.
Hamilton, B. K., Rybicki, L., Abounader, D., Adekola, K., Advani, A., Aldoss, I., … Majhail, N. S. (2017). Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation . -
Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen.
Vardhana, S. A., Hwee, M. A., Berisa, M., Wells, D. K., Yost, K. E., King, B., … Thompson, C. B. (2020). Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nature Immunology. -
A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma
Smith, M. (2021). A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma. TRANSPLANTATION AND CELLULAR THERAPY, 27(1), 2–3. -
-
Posttransplant chimeric antigen receptor therapy
Smith, M., Zakrzewski, J., James, S., & Sadelain, M. (2018). Posttransplant chimeric antigen receptor therapy. BLOOD, 131(10), 1045–1052. -
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Page, D. B., Bourla, A. B., Daniyan, A., Naidoo, J., Smith, E., Smith, M., … Callahan, M. K. (2015). Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 3. -
The Composition of the Intestinal Microbiota Correlates with Response and Toxicity after CAR T cell Immunotherapy in Patients with B-cell Malignancies
Smith, M. (2021). The Composition of the Intestinal Microbiota Correlates with Response and Toxicity after CAR T cell Immunotherapy in Patients with B-cell Malignancies. Nature Medicine . -
Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109a induce less graft-versus-host disease
Smith, M. (2021). Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109a induce less graft-versus-host disease. Blood. -
Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy.
Smith, M. (2021). Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. . Transplantation and Cellular Therapy. -
The gut microbiota is associated with immune cell dynamics in humans
Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., … Xavier, J. B. (2020). The gut microbiota is associated with immune cell dynamics in humans. NATURE, 588(7837), 303–307. -
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., … Mailankody, S. (2020). Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. BLOOD ADVANCES, 4(15), 3776–3787. -
Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans
Masselink, L. E., Erikson, C. E., Connell, N. T., De Castro, L. M., Dent, G. A., Marshall, A. L., … Lee, A. I. (2019). Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans. BLOOD ADVANCES, 3(21), 3278–3286. -
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation
Scordo, M., Bhatt, V., Hilden, P., Smith, M., Thoren, K., Cho, C., … Giralt, S. A. (2019). Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(8), 1526–1535. -
Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Ghosh, A., Smith, M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., … van den Brink, M. R. M. (2017). Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. NATURE MEDICINE, 23(2), 242–249. -
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
Landau, H., Smith, M., Landry, C., Chou, J. F., Devlin, S. M., Hassoun, H., … Comenzo, R. L. (2017). Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. LEUKEMIA, 31(1), 136–142. -
Both naive and memory T cells exert alloreactivity across HLA barriers
Smith, M. (2011). Both naive and memory T cells exert alloreactivity across HLA barriers. Biology of Blood and Marrow Transplantation. -
Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma
Smith, M. (2011). Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma. Advances in Hematology. -
Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States
Shenoy, P. J., Malik, N., Sinha, R., Nooka, A., Nastoupil, L. J., Smith, M., & Flowers, C. R. (2011). Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 11(6), 498–506. -
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., … Ruella, M. (2022). Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. -
Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support.
Lee, A. I., Masselink, L. E., De Castro, L. M., Marshall, A. L., Connell, N. T., Dent, G. A., … Erikson, C. E. (2022). Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances. -
Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar, N., & Smith, M. (2022). Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL. Frontiers in Immunology, 13, 887866. -
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., … Ruella, M. (2022). Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. -
Harnessing ADR T cells to enhance allo-HCT.
Smith, M. (2023). Harnessing ADR T cells to enhance allo-HCT. Blood, 141(10), 1101–1102. -
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy.
Jain, M. D., Smith, M., & Shah, N. N. (2023). How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy. Blood. -
Microbes matter in pediatric allo-HSCT.
Smith, M., & Markey, K. A. (2023). Microbes matter in pediatric allo-HSCT. Blood, 142(16), 1335–1337. -
Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.
Nie, E. H., Su, Y.-J. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W.-K. K., … Frank, M. J. (2024). Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma. Blood Advances. -
Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease.
Lindner, S., Miltiadous, O., Ramos, R. J., Paredes, J., Kousa, A. I., Dai, A., … van den Brink, M. R. (2024). Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. Nature Microbiology. -
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances. -
Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force.
Sharma, A., Czechowicz, A., Mavers, M., Chao, N., DiPersio, J., Reddy, P., … Smith, M. (2024). Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force. Transplantation and Cellular Therapy. -
An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority Patients.
Hill, L. Q. C., & Smith, M. (2024). An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority Patients. NEJM Evidence, 3(4), EVIDe2400022. -
CAR T cell Toxicities: Bedside to Bench - How Novel Toxicities Inform Laboratory Investigations.
Perna, F., Parekh, S., Diorio, C., Smith, M., Subklewe, M., Mehta, R., … Shah, N. N. (2024). CAR T cell Toxicities: Bedside to Bench - How Novel Toxicities Inform Laboratory Investigations. Blood Advances. -
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7). -
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood. -
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., … Miklos, D. B. (2024). CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet (London, England). -
Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults.
Cao, F., Xiu, Y., Mohnasky, M., Serody, J. S., Armistead, P., Dotti, G., … Andermann, T. M. (2024). Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults. MedRxiv : the Preprint Server for Health Sciences. -
The intestinal microbiota and cellular therapy: implications for impact and mechanisms.
Xie, J., & Smith, M. (2024). The intestinal microbiota and cellular therapy: implications for impact and mechanisms. Blood. -
American Society of Hematology: Building a Comprehensive Minority Recruitment and Retention Professional Program.
Rollins, M. R., Warsame, R., Smith, M., Molina, A., Rouce, R. H., Avalos, B. R., … Terrell, D. R. (2026). American Society of Hematology: Building a Comprehensive Minority Recruitment and Retention Professional Program. Blood Advances. -
A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.
Bharadwaj, S., Lowsky, R., Mikkilineni, L., Smith, M., & Weng, W.-K. K. (2024). A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program. Journal of Cancer Education : the Official Journal of the American Association for Cancer Education. -
Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.
Su, Y.-J. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., … Frank, M. J. (2025). Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL. Cancer Discovery.
-
Posttransplant chimeric antigen receptor therapy
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)
- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Practice Locations
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive
875 Blake Wilbur Drive, Clinic E 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records